AGO TUMOR FUNDAMENTALS EXPLAINED

Hormonal therapy continues to be the remedy of initially option for metastatic patients with endocrine-responsive breast most cancers (LoE 1a A, AGO ++). The sequential use in the obtainable drugs relies on the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at time of analysis of relapse is recommended When attainable, to